Noevir Holdings Second Quarter 2025 Earnings: EPS: JP¥48.83 (vs JP¥46.58 in 2Q 2024)

Simply Wall St

May 09, 2025

Noevir Holdings (TSE:4928) Second Quarter 2025 Results

Key Financial Results

Revenue: JP¥15.2b (up 1.5% from 2Q 2024).
Net income: JP¥1.67b (up 4.8% from 2Q 2024).
Profit margin: 11% (in line with 2Q 2024).
EPS: JP¥48.83 (up from JP¥46.58 in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-growth — TSE:4928 Earnings and Revenue Growth May 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Noevir Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.

Performance of the Japanese Personal Products industry.

The company's shares are up 1.2% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Noevir Holdings you should be aware of.

If you're looking to trade Noevir Holdings, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Noevir Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4928

Noevir Holdings

Develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, and Canada.

See The Free Research Report

Flawless balance sheet with proven track record and pays a dividend.

See The Free Research Report